Skip to main content

Table 1 Cancer cells of different origin and type are killed by anti-hTRT CTL

From: Telomerase immunity from bench to bedside: round one

Cell Target

Tumor Origin

Telomerase Activity

HLA-A2

Percent Lysis

 
    

CTL p540

CTL p865

T2+peptide

 

ND

Pos.

59

48

T2

 

ND

Neg.

11

4

MCF7

Breast

Pos.

Pos.

39

41

SKBR3

 

Pos.

Neg.

7

9

SW480

Colon

Pos.

Pos.

12

37

HCT011

 

Pos.

Neg.

9

6

H69

Lung

Pos.

Pos.

41

9

H146

 

Pos.

Neg.

11

5

624

Melanoma

Pos.

Pos.

48

39

1351

 

Pos.

Neg.

12

6

LnCap

Prostate

Pos.

Pos.

44

41

PC3

 

Pos.

Neg.

9

5

  1. From ref [30].